41![BEIKE BIOTECHNOLOGY Patient Case Study Optic Atrophy and Bilateral Optic Neuropathy Female, 24 years old, January-March 2010 Background Age: 24 years old BEIKE BIOTECHNOLOGY Patient Case Study Optic Atrophy and Bilateral Optic Neuropathy Female, 24 years old, January-March 2010 Background Age: 24 years old](https://www.pdfsearch.io/img/2279e272bff66ba29c3fa02dc0d17abd.jpg) | Add to Reading ListSource URL: beikebiotech.comLanguage: English - Date: 2014-06-23 22:47:05
|
---|
42![Gouspillou et al. Longevity & Healthspan 2013, 2:13 http://www.longevityandhealthspan.com/contentREVIEW Open Access Gouspillou et al. Longevity & Healthspan 2013, 2:13 http://www.longevityandhealthspan.com/contentREVIEW Open Access](https://www.pdfsearch.io/img/e8a4be98c0a597e8cabd31067c7539a1.jpg) | Add to Reading ListSource URL: www.longevityandhealthspan.comLanguage: English |
---|
43![Agent-based computational model investigates muscle-specific responses to disuse-induced atrophy Kyle S. Martin, Silvia S. Blemker and Shayn M. Peirce J Appl Physiol 118:, 2015. First published 26 February 2015; Agent-based computational model investigates muscle-specific responses to disuse-induced atrophy Kyle S. Martin, Silvia S. Blemker and Shayn M. Peirce J Appl Physiol 118:, 2015. First published 26 February 2015;](https://www.pdfsearch.io/img/a263dcd6c629de1706adaf957e056190.jpg) | Add to Reading ListSource URL: bme.virginia.eduLanguage: English - Date: 2015-05-22 10:02:10
|
---|
44![Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1 Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1](https://www.pdfsearch.io/img/63a3f4cfdde2c9a4153687d59f202349.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2015-01-27 15:09:34
|
---|
45![Dear Spinal Muscular Atrophy Community Members, We would like to update you on the clinical development of RG7800, an investigational SMN2 splicing modifier that is being studied as a potential treatment for spinal muscu Dear Spinal Muscular Atrophy Community Members, We would like to update you on the clinical development of RG7800, an investigational SMN2 splicing modifier that is being studied as a potential treatment for spinal muscu](https://www.pdfsearch.io/img/10da68200b549ca982314cfb1e68ac34.jpg) | Add to Reading ListSource URL: www.sma-schweiz.chLanguage: English - Date: 2015-05-07 03:16:04
|
---|
46![Bringing CLARITY to gray matter atrophy Bringing CLARITY to gray matter atrophy](https://www.pdfsearch.io/img/143e3b5a788f000bb4fb4e364ce88af3.jpg) | Add to Reading ListSource URL: clarityresourcecenter.orgLanguage: English - Date: 2014-09-02 12:19:12
|
---|
47![SMA Europe 7th Call for Research Projects SMA Europe 7th Call for Research Projects](https://www.pdfsearch.io/img/1b27d2a2e401a00ae1d39a11b8da5356.jpg) | Add to Reading ListSource URL: www.sma-europe.euLanguage: English - Date: 2014-08-01 15:30:46
|
---|
48![Microsoft Word - OspemifeneNDA20120426 Microsoft Word - OspemifeneNDA20120426](https://www.pdfsearch.io/img/3025f39e42085a98bb1a488a845a0145.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:21
|
---|
49![CUSTOMER CASE Dyne Advanced Analytics Kieser Training fights back pain and muscle atrophy with statistics too Kieser Training has also been working with IBM SPSS online survey software sinceSPSS Data Collection We CUSTOMER CASE Dyne Advanced Analytics Kieser Training fights back pain and muscle atrophy with statistics too Kieser Training has also been working with IBM SPSS online survey software sinceSPSS Data Collection We](https://www.pdfsearch.io/img/41d9c070d0b746f7a551a495de55021a.jpg) | Add to Reading ListSource URL: www.spss.chLanguage: English - Date: 2012-11-25 09:31:00
|
---|
50![FOR IMMEDIATE RELEASE U. S. FOOD AND DRUG ADMINISTRATION ACCEPTS SHIONOGI’S OSPEMIFENE NEW DRUG APPLICATION IN VULVAR AND VAGINAL ATROPHY Potential First Oral Alternative to Vaginal Estrogen Treatments FLORHAM PARK, N FOR IMMEDIATE RELEASE U. S. FOOD AND DRUG ADMINISTRATION ACCEPTS SHIONOGI’S OSPEMIFENE NEW DRUG APPLICATION IN VULVAR AND VAGINAL ATROPHY Potential First Oral Alternative to Vaginal Estrogen Treatments FLORHAM PARK, N](https://www.pdfsearch.io/img/edea21357464ccaa85cc9f72decfdf56.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:22
|
---|